Magdolen Youssef-El Soud

Patterns of progression in patients with synchronous oligometastatic non-small cell lung cancer after systemic and local radical treatment

Valentina Bartolomeo, Mandy Jongbloed, Jarno W J Huijs, Andrea Riccardo Filippi et autres

nl, it (code pays fourni par la source)

Patients’ and relatives’ perspectives on the quality of end-of-Life care in advanced cancer: From the final months to bereavement

Moyke A. J. Versluis, Yvette M. van der Linden, Lobke van Leeuwen-Snoeks, Marieke H. J. van den Beuken-van Everdingen et autres

nl, us (code pays fourni par la source)

Effect of treatment sequencing on outcome of patients with non-small cell lung cancer with a synchronous solitary extrathoracic metastasis

Mandy Jongbloed, Ronald AM Damhuis, Wouter H. van Geffen, Peter de Boer et autres

nl (code pays fourni par la source)

Association of metabolic tumour volume (MTV) and total lesion glycolysis (TLG) with survival in patients with oligometastatic non-small-cell lung cancer treated with immunotherapy: a multicentre retrospective study

Francesca Rita Ogliari, Mandy Jongbloed, Rianne D.W. Vaes, Ruud Houben et autres

it, nl (code pays fourni par la source)

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases

Jarno W J Huijs, Anna Sadowska, Juliette Degens, C. Steendam et autres

nl (code pays fourni par la source)

Impact of Immune Checkpoint Inhibitors on Survival Outcomes in Synchronous Oligometastatic Nsclc

Mandy Jongbloed, Valentina Bartolomeo, Martina Bortolot, Shahan Darwesh et autres

High Protein Oral Nutritional Supplements Enable the Majority of Cancer Patients to Meet Protein Intake Recommendations during Systemic Anti-Cancer Treatment: A Randomised Controlled Parallel-Group Study

Anne‐Marie C. Dingemans, Nico van Walree, Franz M.N.H. Schramel, Magdolen Youssef-El Soud et autres

nl, lt, no (code pays fourni par la source)

Multimodal prehabilitation in patients with non-small cell lung cancer undergoing anatomical resection: protocol of a non-randomised feasibility study

Charlotte J. L. Molenaar, Erik M. von Meyenfeldt, Carlijn Tini Ireen de Betue, Rosaline van den Berg et autres

nl (code pays fourni par la source)

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Bonne Biesma et autres

nl (code pays fourni par la source)

Switch Maintenance Gemcitabine after First Line Chemotherapy in Patients with Malignant Mesothelioma: A Randomized Open Label Phase II Trial (NVALT19)

Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Bonne Biesma et autres

nl, us (code pays fourni par la source)